Mary P Ball
 

Mary P Ball M.S., R.N.
Academic Title: Instructor
Primary Appointment: Psychiatry
pball@mprc.umaryland.edu
Location: MPRC, 1-4
Phone: (410) 402-7663
Fax: (410) 402-7198

Personal History

Mary Patricia Ball is the Senior Research Nurse in the Outpatient Research Program and serves as Study Manager for all the clinical trials conducted in the ORP. She completed her undergraduate work at Mount Saint Agnes College and earned her MS in Psychology from Loyola College. She completed the nursing program at Essex Community College and has been certified as a Psychiatric and Mental Health Nurse by the American Nurses Association since 1996.

Research Interests

Ms. Ball's research interests include medical comorbidities and schizophrenia, in particular antipsychotic-induced weight gain. She has been Principal Investigator on two studies in the past which investigated the use of support groups for weight loss in patients taking new-generation antipsychotic medications. Currently, she is PI on three studies: one investigating the effect of different antipsychotics on dietary choices, one investigating the effect of different antipsychotics on response to a variety of foods, and one double-blind study of Atomoxetine combined with a support group and exercise for the treatment of Olanzapine-related weight gain.

Publications

Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine in patients with schizophrenia. American Journal of Psychiatry 153:1092-1094, 1996.
 
Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. American Journal of Psychiatry 155:751-760, 1998.
 
Ball MP, Coons VB, Buchanan RW. A weight management program for treatment of olanzapine related weight gain.  Psychiatric Services 52(7):967-969, 2001.
 
Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan RW. Effects of sustained-release buproprion and supportive group therapy on cigarette consumption in patients with schizophrenia. American Journal of Psychiatry 158:635-637, 2001.
 
Baymiller SP, Ball P, McMahon RP, Buchanan RW. Weight and blood pressure change during clozapine treatment. Clinical Neuropharmacology 25(4):202-206, 2002.
 
Baymiller SP, Ball P, McMahon RP, Buchanan RW.  Serum glucose and lipid changes during the course of clozapine treatment: consideration of concurrent treatment with ß-adrenergic antagonists. Schizophrenia Research 59:49-57, 2003.
 
Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold JM, McMahon RP, Carpenter WT Jr.  Olanzapine treatment of residual positive and negative symptoms. American Journal of Psychiatry 162(1):124-129, 2005.
Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP. Galantamine for the treatment of cognitive impairments in people with schizophrenia. American Journal of Psychiatry 165(1):82-89, 2008.

Conley RR, Boggs DL, Kelly DL, McMahon RP, Feldman S, Ball P, Buchanan RW. The effects of galantamine on psychopathology in chronic stable schizophrenia. Clinical Neuropharmacology, in press.

Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in Schizophrenia: The Relationship to Baseline Symptoms and Changes in Symptom Domains During a One-Year Study. J of Psychopharmacology, in press.

Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Nelson M, Dickinson D, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. Atomoxetine for Neurocognitive Deficits in People with Schizophrenia. J Clinical Psychiatry, under review.



Faculty members: Click here to update your contact information and create a profile.


This site will work and look much better in a modern web browser, such as Internet Explorer 6, Firefox, or Safari 1.2 (Mac)
© University of Maryland School of Medicine